Liminatus Pharma ( (LIMN) ) has released a notification of late filing.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Liminatus Pharma, a pharmaceutical company, has filed a Form 12b-25 indicating a delay in submitting its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The delay is primarily due to the inability to complete financial statements in time for necessary reviews and signatures before the due date. The company anticipates filing the report within five calendar days following the prescribed due date. There are no expected significant changes in financial results from the corresponding period of the previous fiscal year, and forward-looking statements have been noted. Liminatus Pharma continues to work on compliance efforts, with the notification signed by CEO Chris Kim.
More about Liminatus Pharma
Average Trading Volume: 616,420
Technical Sentiment Signal: Sell
Current Market Cap: $111.5M
Learn more about LIMN stock on TipRanks’ Stock Analysis page.